EU-Cuba Biotech Partnership Launches Regional Vaccine Production Boost

The biotech sector in 2025 faces significant challenges and opportunities globally. Early-stage biotechs are struggling with limited access to capital, leading to a contraction in deal values and forcing difficult strategic decisions that may delay critical therapy development, as reported by GlobalData. Meanwhile, initiatives such as Saudi Arabia's new Biotech Accelerator Program, developed in partnership with BioLabs, and Cuba's EU-backed Biotechnology Program aim to strengthen innovation, production capacity, and regulatory standards in their regions. Australia’s Cauldron was recognized as a 2025 Technology Pioneer by the World Economic Forum, highlighting its role in advancing fermentation biotech. In Europe, particularly Germany, biotech company formation lags behind despite economic strength, with a notable shift from early-stage to later-stage investments, indicating a need for increased support to boost growth. Together, these developments reflect a complex global biotech landscape marked by financial constraints, emerging innovation hubs, and efforts to enhance industry infrastructure and capabilities.